Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule belonging to the indole class of organic compounds. It is also known as Indirubin_E804 and has been studied primarily as a kinase inhibitor. Structural studies show it binds to and inhibits protein kinases, notably glycogen synthase kinase 3 beta (GSK3B), which plays a role in various cellular processes including metabolism and neurodegenerative disease pathways. The compound has been co-crystallized with calcium/calmodulin-dependent protein kinase from Cryptosporidium parvum, indicating its use in structural biology for probing kinase function[1][3][5]. Its primary mechanism of action is inhibition of serine/threonine-protein kinases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one.